Zidovudine is indicated for the Treatment of-

• Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. 
• Prevention of maternal-fetal HIV-1 transmission

HIV

• Treatment of HIV-1 infection: Adults: 600 mg/day in divided doses with other antiretroviral agents.
• Pediatric patients (6 weeks to <18 years of age): Dosage should be calculated based on body weight not to exceed adult dose. 
• Prevention of maternal-fetal HIV-1 transmission:  Specific dosage instructions for mother and infant.
• Patients with severe anemia and/or neutropenia: Dosage interruption may be necessary.
• Renal Impairment – Recommended dosage in hemodialysis or peritoneal dialysis patients is 100 mg every 6 to 8 hours

• Hematologic toxicity/bone marrow suppression including neutropenia and severe anemia have been associated with the use of zidovudine. 
• Symptomatic myopathy associated with prolonged use of zidovudine.
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including Zidovudine. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. 
• Exacerbation of anemia has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised.
• Hepatic decompensation, (some fatal), has occurred in HIV-1/HCV co-infected patients receiving combination anti-retroviral therapy and interferon alfa with/without ribavirin. Discontinue zidovudine as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both.
• Zidovudine should not be administered with other zidovudine-containing combination products. 
• Immune reconstitution syndrome and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy.